NASDAQ: ONCO
Onconetix Inc Earnings Dates, Reports, Calls

Onconetix earnings were -$51.6M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest ONCO earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$3.8M, down 73.2% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ONCO reported annual earnings of -$37.4M, with 176.8% growth.

ONCO earnings history

Current Revenue
$1.9M
Current Earnings
-$51.6M
Current Profit Margin
-2,758.7%

ONCO Return on Equity

Current Company
N/A
Current Industry
19.9%
Current Market
35%

ONCO undefined

Current Company
-72.7%
Current Industry
1.3%
ONCO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ONCO announces earnings.

ONCO undefined

Current Company
-113.09%
Current Industry
14.3%
ONCO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ONCO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ONCO-$49.74M-$51.60MN/A-$99.33
SCPX-$19.67M-$28.81MN/A-$102.41
VINC-$28.98M-$30.07MN/A-$15.85
GRI-$10.14M-$10.12MN/A-$55.21
BDRX-$7.32M-$7.54MN/A-$0.13

Onconetix Earnings Reports & History FAQ

What were Onconetix's earnings last quarter?

Onconetix (NASDAQ: ONCO) reported Q3 2024 earnings per share (EPS) of -$2.93, up 76% year over year. Total ONCO earnings for the quarter were -$3.83 million. In the same quarter last year, Onconetix's earnings per share (EPS) was -$12.21.

If you're new to stock investing, here's how to buy Onconetix stock.

Is Onconetix profitable or losing money?

As of the last Onconetix earnings report, Onconetix is currently losing money. Onconetix's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$51.60 million, a 182.35% increase year over year.

What was ONCO's earnings growth in the past year?

As of Onconetix's earnings date in Q2 2025, Onconetix's earnings has grown year over year. ONCO earnings in the past year totalled -$51.60 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.